ANVS Stock Analysis: Buy, Sell, or Hold?
ANVS - Annovis Bio, Inc.
$2.60
-0.10 (-3.70%)
▼
5d:
-10.34%
30d:
-28.77%
90d:
+23.81%
WAIT
LOW Confidence
Last Updated: February 3, 2026
Earnings: Mar 20, 2026
Get Alerted When ANVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ANVS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ANVS is down 10.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ANVS is down 10.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ANVS is currently trading at $2.60, which is considered oversold relative to its 30-day fair value range of $2.81 to $3.64.
Technical Outlook: Technically, ANVS is in a uptrend. The price is currently testing key support at $2.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: ANVS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.75 (+428.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANVS is in a uptrend. The price is currently testing key support at $2.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: ANVS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.75 (+428.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.81 -
$3.64
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 428.8% below Wall St target ($13.75)
- WARNING: Recommendation downgraded due to -10.3% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.81 -
$3.64
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.64
(24.5%)
Support & Resistance Levels
Support Level
$2.55
Resistance Level
$3.19
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.94
Wall Street Target
$13.75
(+428.8%)
Last updated: February 04, 2026 5:52 AM ET
Data refreshes hourly during market hours. Next update: 6:52 AM
Data refreshes hourly during market hours. Next update: 6:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
